Human cellexp DKK-1, Human Recombinant proteins
- Known as:
- Human cellexp DKK-1, Human Recombinant proteins
- Catalog number:
- 7132-50
- Product Quantity:
- 50 μg
- Category:
- Proteins
- Supplier:
- Biovis
- Gene target:
- Human cellexp DKK-1 Recombinant proteins
Related genes to: Human cellexp DKK-1, Human Recombinant proteins
- Gene:
- DKK1 NIH gene
- Name:
- dickkopf WNT signaling pathway inhibitor 1
- Previous symbol:
- -
- Synonyms:
- SK, DKK-1
- Chromosome:
- 10q21.1
- Locus Type:
- gene with protein product
- Date approved:
- 2000-09-01
- Date modifiied:
- 2018-06-28
Related products to: Human cellexp DKK-1, Human Recombinant proteins
Related articles to: Human cellexp DKK-1, Human Recombinant proteins
- The European COSMOS study, which included 6,797 haemodialysis patients from 20 countries, demonstrated that elevated PTH levels were associated with a higher risk of mortality in diabetic patients compared to non-diabetic ones. Elevated PTH levels have been linked to inflammatory processes. This study aimed to analyse, in epigastric arteries of dialysis patients, whether diabetes and elevated PTH levels might synergistically modulate the expression of inflammatory and vascular calcification (VC) markers through ADAM17 and/or its inhibitor, TIMP3. - Source: PubMed
Publication date: 2025/09/15
Martín-Carro BeatrizPanizo SaraGarcía-Castro RaúlFernández-Villabrille SaraGonzález-García NereaRodríguez-García MinervaGarcía Natalia MenéndezFernández-Gómez Jesús MHévia-Suárez Miguel ADelgado EliasSánchez-Álvarez EmilioNavarro-González Juan FNaves-Díaz ManuelCarrillo-López NataliaFernández-Martín José LAlonso-Montes Cristina - Recent advancements in bone tissue biomarker research have identified 2 promising molecules: Dickkopf-1 and secreted Frizzled-Related Protein 5. This study aims to evaluate the levels of these biomarkers in gingival crevicular fluid in periodontal health, gingivitis, and periodontitis and to assess the effects of non-surgical periodontal treatment on these biomarkers. - Source: PubMed
Publication date: 2025/09/16
Acipinar SukranBaris Kubilay - Rheumatic diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), significantly increase the risk of cardiovascular disease (CVD), with affected patients exhibiting a 2-3-fold higher risk compared to the general population. This elevated risk is primarily driven by chronic inflammation and accelerated atherosclerosis, which are not fully captured by traditional cardiovascular risk calculators. RA patients face cardiovascular risks similar to those of type 2 diabetics, while SLE patients, particularly young women, have a dramatically increased risk of myocardial infarction. These conditions challenge the conventional understanding of CVD risk, as traditional factors like hypertension, dyslipidemia, and smoking do not fully account for the excess risk observed. This has led to growing interest in the use of new biomarkers and advanced imaging technologies to improve risk stratification and early detection of cardiovascular involvement. This review examines the pathophysiological mechanisms that link rheumatic diseases with cardiovascular risk. Chronic inflammation, immune dysregulation, and vascular dysfunction are central to the accelerated atherosclerosis and myocardial damage seen in RA and SLE. Key proinflammatory cytokines, including Tumor Necrosis Factor- Alpha (TNF-α), Interleukin (IL) IL-6, and IL-17, contribute to endothelial dysfunction and oxidative stress, exacerbating cardiovascular risk. In addition, biomarkers such as high-sensitivity C-reactive protein (hs-CRP), NT-proBNP, and troponins are valuable for detecting subclinical cardiac involvement and predicting adverse cardiovascular outcomes. Emerging biomarkers like IL-32, Dickkopf-related protein 1 (DKK-1), and galectin-3 also show potential in further refining risk assessment, particularly for atherosclerosis and myocardial fibrosis in rheumatic diseases. Advanced imaging methods, such as transthoracic echocardiography (TTE), carotid ultrasonography, cardiac MRI (CMR), and coronary CT angiography (CCTA), provide key insights into subclinical cardiovascular changes in rheumatic disease patients. These techniques enable the detection of myocardial inflammation, fibrosis, and early atherosclerosis, helping guide clinical decisions and preventive interventions. Despite advancements, traditional cardiovascular risk calculators often underestimate CVD risk in rheumatic disease patients, leading to the use of adjusted models, such as EULAR-endorsed 1.5× risk multiplier for RA patients. These adjustments, along with the integration of biomarkers and imaging findings, can help identify high-risk individuals and prompt early interventions, such as statin therapy. However, challenges remain, including the cost and accessibility of some imaging methods, the heterogeneous risk profiles across different rheumatic diseases, and the need for more prospective trials to evaluate the effectiveness of biomarkers and imaging in clinical practice. In conclusion, incorporating biomarkers and advanced imaging techniques into cardiovascular risk assessment provides a more accurate method for managing CVD in rheumatic disease patients. These approaches allow for more personalized care, helping reduce the increased CVD mortality seen in this population. Future research should focus on refining multi-biomarker algorithms, improving imaging technology, and conducting intervention trials to optimize cardiovascular outcomes in rheumatic disease patients. - Source: PubMed
Publication date: 2025/08/11
Shah Freya HAgrawal SiddharthTated Ritu CMaheta DarshilkumarNaqvi Syed - Acute kidney injury (AKI) is a group of common clinical syndromes characterized by a rapid decline in renal function over a short period of time. At present, the treatment methods are limited, and research is needed to identify drugs that could alleviate renal ischemia-reperfusion (I/R) injury. Tetramethylpyrazine (TMP) is a bioactive alkaloid extracted from the Chinese herbal medicine Chuanxiong. TMP is known to possess various anti-inflammatory and cardiovascular and renal protective effects; however, the therapeutic molecular targets are still unclear. In the present study, using a rat renal I/R model, the effects of TMP on renal injury, dickkopf-1 (DKK1) expression, Wnt/β-catenin signaling and apoptosis were evaluated through morphological examination, renal function tests, western blotting, immunohistochemistry and TUNEL assays. It was determined that TMP ameliorated tubular pathologic injury and improved renal function in rats following renal I/R. In addition, in rats following I/R, TMP promoted the expression of DKK1, an inhibitor of the Wnt/β-catenin signaling pathway, in renal tissues, activated the Wnt/β-catenin signaling pathway in kidney tissues and reduced apoptosis of renal cells. To the best of our knowledge, the present study is the first to investigate the regulatory effects of TMP on DKK1 and the Wnt/β-catenin signaling pathway, revealing that TMP could attenuate AKI by activating Wnt/β-catenin signaling independent of the inhibitory effect of DKK1. - Source: PubMed
Publication date: 2025/08/27
Wang XiaohuiChang XiaoxiaYang DonglinZhang LixiaGuo ZijieSun XuhongLi AiqunNi YanboDu Pengchao - Rejection following liver and kidney transplantation remains a major barrier to long-term graft survival. Early and reliable detection of rejection is crucial for optimizing patient outcomes and guiding personalized therapeutic approaches. Despite ongoing efforts, currently available serum-based biomarkers often fail to provide sufficient sensitivity and specificity for early diagnosis. Dickkopf-1 (DKK1) and cytoskeleton-associated protein 4 (CKAP4) are molecules involved in Wnt signaling, immune regulation, fibrosis, and tissue remodeling. Their upregulation has been associated with inflammatory and fibrotic processes in various pathological contexts. These properties make them strong candidates as novel molecular biomarkers in transplant rejection. This prospective observational study aimed to investigate the association between DKK1 and CKAP4 mRNA expression levels and the occurrence of rejection in liver and kidney transplant recipients. Peripheral blood samples from 55 transplant patients diagnosed with rejection (30 kidney, 25 liver) and 35 healthy controls were analyzed for DKK1 and CKAP4 mRNA expression using real-time polymerase chain reaction. Expression profiles were evaluated in relation to clinical and histopathological parameters. DKK1 and CKAP4 mRNA expression levels were significantly elevated in transplant recipients with rejection compared with healthy controls. In kidney transplant patients, both markers showed increased expression, although no significant histopathological correlations were detected. In liver transplant recipients, DKK1 expression was significantly associated with cellular rejection and portal inflammation. These findings suggest that DKK1 and CKAP4 may serve as promising molecular biomarkers for transplant rejection monitoring. In particular, DKK1 may provide additional diagnostic value in identifying cellular rejection and portal inflammation in liver grafts. Further multicenter studies are required to validate these results and assess their potential for clinical application. - Source: PubMed
Altundaş NecipBalkan EdaKizilkaya MuratAltunok MuratAksungur NurhakKara SalihDemirci ElifÖztürk Gürkan